Drew RC, Muller MD, Blaha CA, Mast JL, Herr MD, Stocker SD, Sinoway LI. Aspirin augments carotid-cardiac baroreflex sensitivity during muscle mechanoreflex and metaboreflex activation in humans. Muscle mechanoreflex activation decreases the sensitivity of carotid baroreflex (CBR)-heart rate (HR) control during local metabolite accumulation in humans. However, the contribution of thromboxane A2 (TXA2) toward this response is unknown. Therefore, the effect of inhibiting TXA2 production via low-dose aspirin on CBR-HR sensitivity during muscle mechanoreflex and metaboreflex activation in humans was examined. Twelve young subjects performed two trials during two visits, preceded by 7 days' low-dose aspirin (81 mg) or placebo. One trial involved 3-min passive calf stretch (mechanoreflex) during 7.5-min limb circulatory occlusion (CO). In another trial, CO was preceded by 1.5 min of 70% maximal voluntary contraction isometric calf exercise to accumulate metabolites during CO and stretch (mechanoreflex and metaboreflex). HR (ECG) and mean arterial pressure (Finometer) were recorded. CBR function was assessed using rapid neck pressures ranging from ϩ40 to Ϫ80 mmHg. Aspirin significantly decreased baseline thromboxane B2 production by 84 Ϯ 4% (P Ͻ 0.05) but did not affect 6-keto prostaglandin F1␣. Following aspirin, stretch with metabolite accumulation significantly augmented maximal gain (GMAX) and operating point gain (GOP) of CBR-HR (GMAX; Ϫ0.71 Ϯ 0.14 vs. Ϫ0.37 Ϯ 0.08 and GOP; Ϫ0.69 Ϯ 0.13 vs.
mation regarding the mechanical and metabolic conditions within skeletal muscle via projections to the dorsal horn of the spinal cord and up to the cardiovascular control centers in the medulla oblongata located in the brain stem. This feedback is integrated with baroreceptive afferent feedback in the nucleus tractus solitarii (NTS), which modulates sympathetic and parasympathetic outflow from the brain, leading to reflex changes in heart rate (HR) and mean arterial blood pressure (MAP) (32) .
Previous findings suggest that muscle mechanoreceptors feedback via the spinal cord to the NTS, and this inhibitory input at the level of the NTS reduces cardiac vagal outflow. Passive tendon stretch to evoke the muscle mechanoreflex stimulates some of the same mechanoreceptors that are activated during muscular contraction in decerebrated cats (15) . Mechanical stimulation of muscle via stretch increases HR and MAP in humans (12, 13) and animals (27, 35) and, importantly, decreases spontaneous baroreflex sensitivity in humans (9) . The increase in HR with stretch can be abolished with glycopyrrolate, a muscarinic ACh receptor antagonist (14) , suggesting that stretch inhibits cardiac vagal activity. In the presence of local metabolite accumulation, passive stretch further increases HR and MAP and decreases spontaneous baroreflex sensitivity in humans, suggesting that these metabolites sensitize muscle mechanoreceptors (2, 9) . This is in agreement with animal studies showing increased mechanoreceptor activity in the presence of metabolites produced during exercise (19, 20) . Additionally, passive stretch during local metabolite accumulation decreases the maximal gain (sensitivity) of carotid baroreflex (CBR) control of HR in humans, without affecting the gain of CBR control of MAP (10) . Collectively, metabolite sensitization of muscle mechanoreceptors appears to increase the mechanoreceptor-induced inhibitory feedback, further reducing cardiac vagal outflow. Consequently, this decreases the sensitivity of CBR control of HR during concurrent muscle mechanoreflex and metaboreflex activation.
Several metabolites are produced by skeletal muscle during exercise, including lactic acid, hydrogen ions, potassium, and products of arachidonic acid breakdown (17) . Arachidonic acid is converted via the cyclooxygenase (COX) enzyme to prostaglandins and thromboxane A 2 (TXA 2 ). Muscle sympathetic nerve activity and renal vascular resistance responses to handgrip (23) , as well as passive forearm stretch following fatiguing handgrip (8, 25) , can be reduced during COX inhibition with indomethacin or ketorolac in healthy humans. This attenuation also occurs in patients with heart failure (24) . A TXA 2 mimetic has been shown to stimulate group III and IV afferents in cats (21) . However, the specific contribution of TXA 2 to metabolite sensitization of muscle mechanoreceptors in humans is unknown. Low-dose aspirin (Ͻ100 mg) preferentially inhibits the COX-1 isoenzyme that causes TXA 2 production and does so without inhibiting prostaglandin production (3, 28) . Considering this background, we examined the effect of inhibiting TXA 2 production via low-dose aspirin on the sensitivity of CBR control of HR and MAP during passive calf muscle stretch with local metabolite accumulation in young, healthy humans. Aspirin could inhibit TXA 2 production and, therefore, reduce the level of metabolite sensitization of muscle mechanoreceptors. The consequent cardiac vagal inhibition caused by stretch with concurrent local metabolite accumulation would be attenuated, preventing the decrease in maximal gain of CBR-HR during stretch with metabolite accumulation with aspirin compared with placebo. Therefore, we hypothesized that aspirin would inhibit TXA 2 production, preventing a decrease in CBR-HR maximal gain during stretch and metabolite accumulation with aspirin compared with placebo.
METHODS
Ethical approval. The experimental protocol was approved by the Institutional Review Board of the Penn State Milton S. Hershey Medical Center and conformed to the Declaration of Helsinki. The studies were performed in the Clinical Research Center of the Penn State Milton S. Hershey Medical Center. The purpose and risks involved were explained to all subjects before written informed consent was obtained.
Subjects. Twelve young, healthy subjects (6 men and 6 women; means Ϯ SE; age 27 Ϯ 1 yr, height 1.75 Ϯ 0.03 m, and weight 74 Ϯ 5 kg) participated in this study. All subjects were normotensive, had no history of cardiovascular disease, were not currently taking any medications, and were in good health. Subjects were asked to refrain from performing strenuous exercise, ingesting caffeine and alcohol for 24 h, and ingesting food for 8 h prior to their study visits.
Experimental protocol. Subjects were seated in a semisupine position in our specifically designed Leg Exercise And Passive Stretch (LEAPS) system. The right leg was flexed by 30°with the lower leg positioned parallel to the ground and the foot strapped to the footplate. Straps were used to fix the foot against the footplate to minimize heel lift during calf exercise and passive stretch. At the beginning of each visit before performing the trials, the range of passive dorsiflexion of the ankle joint was assessed by pivoting the footplate as far as was comfortable. This range was then clamped on the LEAPS system, so the same level of passive calf stretch could be applied during the two trials performed during each visit. Maximal voluntary contraction (MVC) of the calf plantarflexor muscles was assessed by recording the maximal torque produced when subjects pushed as hard as possible against the footplate. This was repeated 3-5 times with each effort being separated by 1 min, and the largest torque was taken to indicate subjects' MVC. 70% of each subject's MVC was calculated and set on a torque display box in front of the subject, so they could visualize the level of torque produced during the exercise phase in the 70% MVC trial.
Subjects were habituated to the experimental protocol and procedures during a familiarization visit. Subjects attended two further experimental visits, in which they performed two trials during both visits. Visits were preceded by either 7 days of low-dose aspirin (81 mg) or placebo and were separated by at least 4 wk to allow for washout of the aspirin in-between visits, as well as control for menstrual cycle phase within each female subject. All female subjects had regular cycles and were at a similar day in their cycle for both of their experimental visits. The order of these visits was counterbalanced, as was the order of the two trials within each visit. A schematic diagram of the experimental protocol for these trials is shown in Fig. 1 . After subjects were settled for at least 10 min, the trial began with a 5-min baseline phase. During this time, a blood sample was taken to measure baseline thromboxane B 2 (TXB2) levels. Subjects then either continued to rest (0% MVC trial) or performed isometric right calf exercise at 70% MVC for 1.5 min (70% MVC trial). Five seconds before exercise was stopped, a cuff was inflated to suprasystolic pressure around the right thigh to occlude blood flow and trap metabolites produced during exercise within the lower leg. This circulatory occlusion (CO) remained for 7.5 min. Three-and-a-half minutes into CO, the right calf muscle was passively stretched by pivoting the footplate to the preset level, and this was maintained for 3 min (COϩstretch). The foot was then returned to its original position and after a further minute of CO, the thigh cuff was deflated. This was followed by a 2-min recovery phase. Therefore, these two trials included phases of muscle mechanoreflex activation (0% MVC trial) or concurrent muscle mechanoreflex and metaboreflex activation (70% MVC trial).
Cardiovascular and experimental measurements. R-R interval was measured using a three-lead electrocardiogram (ECG; Cardiocap/5, GE Healthcare, Waukesha, WI), from which HR was derived. MAP was measured beat-to-beat using a finger cuff (Finometer, FMS, Arnhem, Netherlands) and was calibrated to baseline MAP measurements taken in triplicate before each trial using an arm cuff (Philips SureSigns VS3; Andover, MA). Respiratory movements were measured using a pneumography belt placed around the abdomen. Torque levels produced during calf exercise and passive stretch were measured using a load cell on the footplate. The pressure generated in the neck collar (see Carotid baroreflex assessment) was measured by a transducer fitted to the front of the collar. An analog-to-digital converter [Cambridge Electronic Design (CED) 1401plus; CED, Cambridge, UK] was used to sample ECG, Finometer, pneumograph, torque, and neck collar pressure signals at 1,000 Hz. Data were recorded and displayed using Spike2 software (CED, Cambridge, UK), which was used for off-line analysis.
Carotid baroreflex assessment. Carotid baroreflex control of HR and MAP was assessed using a variable pressure neck chamber, where a range of positive and negative pressures were applied via a rubberlined malleable collar that was secured around the front two-thirds of the neck with a Velcro strap (1, 10, 11, 30) . A rapid series of 12 computer-controlled pressures lasting 500 ms each were produced by a vacuum and delivered through the collar. These pressures were
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REST/EX REST OCCLUSION STRETCH 0min 5min 6.5min 10min 13min 14min 16min triggered off consecutive R waves, each delayed 50 ms after the R wave. Pressures were in the order ϩ40, ϩ40, ϩ40, ϩ40, ϩ20, ϩ10, 0, Ϫ10, Ϫ20, Ϫ40, Ϫ60, and Ϫ80 mmHg and occurred during an end-expiratory breath-hold lasting around 10 s. Neck pressures were applied 3 times during the rest and stretch phases of the protocol, with at least 1-min rest between each series. HR and MAP responses to neck pressures were plotted against estimated carotid sinus pressure (ECSP), which was calculated as prestimulus MAP minus neck collar pressure; this produced carotidcardiac (CBR-HR) and carotid-vasomotor (CBR-MAP) stimulus-response function curves, respectively. Individual responses were fitted to a four-parameter logistic function model (22) , which incorporated the following equation:
where A1 is the responding range HR or MAP (maximum response minus minimum response), A2 is the gain coefficient, A3 is the ECSP required to elicit an equal pressor or depressor response (centering point), and A4 is the minimal response of HR and MAP. Responses were fitted to this model by a nonlinear least-squares regression, which minimized the sum of squares error to predict a curve of "best fit" for each individual subject's response. Only curves with a correlation coefficient of r 2 Ͼ 0.95 were accepted. The overall fit of the curves was similar for low-dose aspirin and placebo with r 2 values of 0.978 Ϯ 0.004 aspirin and 0.989 Ϯ 0.004 placebo for HR and 0.986 Ϯ 0.003 aspirin and 0.982 Ϯ 0.004 placebo for MAP at 70% rest, and 0.976 Ϯ 0.004 aspirin and 0.986 Ϯ 0.005 placebo for HR, and 0.980 Ϯ 0.004 aspirin and 0.994 Ϯ 0.004 placebo for MAP during 70% COϩstretch. Threshold and saturation are the minimal and maximal ECSPs, respectively, that elicit a reflex response in HR or MAP and were calculated as follows: Threshold ϭ Ϫ2/A 2 ϩ A3 Saturation ϭ ϩ2/A2 ϩ A3. These calculations are the ECSPs at which HR or MAP are within 5% of their minimal or maximal response (5) . Maximal gain (G MAX) of the stimulus-response function curves is the gain at the centering point and used as an index of overall CBR responsiveness. G MAX was calculated using the following equation: GMAX ϭ ϪA1 ϫ A2/4. Operating point (OP) was defined as the prestimulus HR or MAP. OP gain (GOP) is a measure of responsiveness at the OP of the function curve and was calculated as follows, with ECSP OP being the ECSP at the OP:
Low-dose aspirin treatment and measurement. Before each of their two experimental visits, subjects took a 7-day course of either lowdose aspirin (81 mg) or placebo (sucrose capsules). We chose to use this dose of aspirin as it is used clinically to reduce the incidence of myocardial infarction and stroke in susceptible populations, such as patients with cardiovascular disease and those at risk of developing cardiovascular disease. Low-dose aspirin inhibits platelet production of TXA 2, and this antithrombotic effect reduces the likelihood of cardiovascular events (29) .
Seven-day treatment of 81-mg aspirin has been shown to irreversibly inhibit platelet production of TXA 2. Around 10% of platelets are newly formed every day so once aspirin treatment is stopped, it takes ϳ10 days for 100% of platelets to function normally (3, 28) . Subjects Table 1 . Values for contraction, stretch, and ankle range of motion for the placebo 0%, placebo 70%, aspirin 0%, and aspirin 70% trials were instructed to take one capsule each morning, with their last dose being taken on the day before their visit. They were also asked not to take any aspirin or other nonsteroidal anti-inflammatory drugs other than the treatment that we provided them in the 2 wk preceding each of their two experimental visits (16, 29) . TXA 2 is rapidly (within ϳ30s) hydrolyzed to TXB2 in the blood, so it is difficult to measure. Therefore, measuring TXB2 levels is the standard method for assess-ing COX blockade (4) . An intravenous catheter was placed into a vein at the antecubital fossa of one arm to draw blood samples to measure baseline plasma TXB 2 levels to assess the effectiveness of the aspirin treatment. TXB 2 levels were measured using an enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI). Baseline 6-keto prostaglandin F 1␣ (PGF1␣) levels were also measured using an enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI) in a subset of six subjects (3 men and 3 women). Data and statistical analyses. Raw data files were analyzed using custom-written script files to produce beat-to-beat values for R-R interval, HR, systolic blood pressure, diastolic blood pressure, and MAP. Group means were calculated for each phase and each trial. End-exercise values were calculated from the last 15 s of exercise. The first 30 s following the end of exercise was excluded from data analysis, so only steady-state data was included in the CO phase. Neck collar pressures were measured directly from raw data files, and CBR function curves and their parameters were derived using SigmaPlot (Systat Software, San Jose, CA). Each series of 12 pressures (three performed during rest and three during stretch) was fitted to the regression model to produce a CBR function curve for HR and MAP. If there were two or three curves that met the inclusion criteria for the correlation coefficient of r 2 Ͼ 0.95 within each phase, the parameters for these curves were averaged. This produced average CBR-HR and CBR-MAP curves for both the rest and stretch phases in each trial, which consisted of data from one, two, or three pressure series. All values are expressed as means Ϯ SE. Significant differences in cardiovascular and CBR variables were identified using repeatedmeasures ANOVA and where found, post hoc analysis using paired-samples t-tests with a Bonferroni correction was performed. Significant differences in TXB 2 and PGF1␣ levels were identified using paired-sample t-tests. Statistical significance was set at P Ͻ 0.05, and all statistical analysis was performed using SPSS (IBM, Armonk, NY).
RESULTS

Contraction and stretch values.
Values for contraction, stretch, and ankle range of motion are shown in Table 1 . MVCs were similar in the two 70% trials, as were torques generated during 70% exercise. Range of motion of the right ankle was similar in all trials. Peak torques within the first 5 s of stretch and torques at the end of stretch were similar in all trials, as were their relative magnitudes compared with the corresponding MVC.
Cardiovascular variables, TXB 2 , and PGF 1␣ . Baseline HR and blood pressures are shown in Table 2 . HR, MAP, systolic pressure, and diastolic blood pressure were similar during baseline in all trials. Aspirin did not affect any baseline Fig. 2A ) but did not affect PGF 1␣ levels (Fig. 2B) . The intra-assay coefficient of variation for TXB 2 was 19 Ϯ 2% and for PGF 1␣ , it was 16 Ϯ 3%.
Relative changes from baseline in HR during all four trials are shown in Fig. 3A . 70% exercise significantly increased HR (P Ͻ 0.05), and this increase was similar with placebo and aspirin. Following the end of exercise, HR fell but remained elevated above baseline during CO (P Ͻ 0.05). Stretch increased HR from CO levels by a similar magnitude in all trials (P Ͻ 0.05). HR remained above baseline during CO after stretch and recovery.
Relative changes from baseline in MAP during all four trials are shown in Fig. 3B . 70% exercise significantly increased MAP (P Ͻ 0.05), and this increase was similar with placebo and aspirin. Following the end of exercise, MAP fell but remained elevated above baseline during CO (P Ͻ 0.05). MAP continued to be raised above baseline during stretch and then returned to baseline when circulatory occlusion ended.
CBR control of HR. Logistic model parameters and derived variables describing CBR-HR control during rest and COϩstretch in all four trials are shown in Tables 3 and 4 , respectively. Stimulus-response function curves for CBR-HR during rest and COϩstretch in placebo 70% and aspirin 70% are shown in Fig. 4 . Compared with rest, stretch increased OP and reset CBR-HR curves upward and rightward in all trials (P Ͻ 0.05). In the 70% trials, G MAX and G OP were significantly greater during stretch with aspirin compared with placebo (P Ͻ 0.05; Fig. 5, A and B,  respectively) .
CBR control of MAP. Logistic model parameters and derived variables describing CBR-MAP control during rest and COϩstretch in all four trials are shown in Tables 5 and 6 , respectively. Stimulus-response function curves for CBR-MAP during rest and COϩstretch in placebo 70% and aspirin 70% are shown in Fig. 6 . Compared with rest, stretch increased OP and reset CBR-MAP curves upward and rightward in all trials (P Ͻ 0.05). G MAX and G OP were similar during stretch in all trials.
DISCUSSION
The main finding in this study was that aspirin increased CBR-HR sensitivity during concurrent muscle mechanoreflex and metaboreflex activation in young, healthy humans. Both G MAX and G OP of CBR-HR were greater during passive stretch with concurrent local metabolite accumulation with aspirin compared with placebo. This increase in CBR-HR sensitivity only occurred when muscle mechanoreflex and metaboreflex activation were combined with aspirin treatment. This finding suggests that TXA 2 plays a role in metabolite sensitization of muscle mechanoreceptors, which can alter CBR control of HR in humans.
We have previously shown that passive stretch during local metabolite accumulation decreases G MAX of CBR-HR in young, healthy humans (10) . This decrease in G MAX only occurred when metabolites were present in the muscle being stretched. This suggested that metabolite sensitization of muscle mechanoreceptors augmented the inhibitory feedback to the NTS due to stretch and consequently reduced cardiac vagal outflow, hence, the decreased CBR-HR sensitivity. It is likely that this occurred in the face of increased baroreceptive afferent input to the NTS due to a higher MAP caused by muscle metaboreflex activation (33) . This excitatory input to the NTS would usually increase cardiac vagal outflow in an attempt to normalize the elevated MAP. However, it appeared that the augmented inhibitory feedback due to metabolite sensitization of muscle mechanoreceptors overpowered the excitatory baro-receptor input at the level of the NTS, resulting in decreased G MAX of CBR-HR. In this study, low-dose aspirin significantly decreased TXB 2 production but did not affect PGF 1␣ , indicating that TXA 2 production was almost completely abolished. With similar MAPs during CO due to muscle metaboreflex activation and the same mechanical stimulus applied to the calf muscle in both the placebo 70% and aspirin 70% trials, G MAX and G OP were significantly greater during stretch with metabolite accumulation when TXA 2 was inhibited. This implies that removing TXA 2 's contribution to metabolite sensitization of muscle mechanoreceptors reduces the inhibitory feedback due to mechanoreflex activation, which prevents the decrease in G MAX of CBR-HR that we have shown previously. This would be expected to result in similar G MAX of CBR-HR during stretch with metabolite accumulation and rest in the aspirin 70% trial. Surprisingly, not only was the decrease in G MAX of CBR-HR prevented during stretch with metabolite accumulation with aspirin compared with placebo as hypothesized, aspirin augmented G MAX of CBR-HR during stretch with metabolite accumulation above resting levels, which was not hypothesized. It is unknown whether low-dose aspirin affected any other variables that can influence CBR-HR sensitivity, but it remains likely that TXA 2 plays a role in metabolite sensitization of muscle mechanoreceptors, which can alter CBR-HR sensitivity.
Stretch increased HR by ϳ1-2 beats/min from CO levels in all trials. These changes were small, but the most striking change during stretch with concurrent metabolite accumulation was the augmented CBR-HR G MAX with low-dose aspirin. It appears that it is the change in HR in response to a change in MAP that is altered with low-dose aspirin more so than the absolute level of vagal tone per se, as absolute HR was similar between aspirin and placebo. In other words, CBR-HR sensitivity is affected more than the overall HR during stretch with metabolite accumulation with low-dose aspirin. Examining precisely how these neural inputs were centrally processed was outside the scope of this study. However, it may be that there are some muscle mechanoreceptors that are more sensitive to TXA 2 than other metabolites and project via the dorsal horn of the spinal cord primarily to the NTS. If these mechanoreceptors are stimulated less due to reduced TXA 2 production, the resultant inhibitory feedback to the NTS would be attenuated. This could allow the excitatory baroreceptive afferent input to (31) . This could explain the increased CBR-HR G MAX during stretch with concurrent metabolite accumulation with low-dose aspirin.
The effects of COX inhibition on cardiovascular function have been examined in numerous studies. In young, healthy humans, intravenous ketorolac infusion did not affect cardiovagal or sympathetic baroreflex sensitivity in response to sodium nitroprusside and phenylephrine infusions (modified Oxford technique) (26) . However, oral indomethacin attenuated baroreflex sensitivity in response to norepinephrine infusion (36) . In this study, low-dose aspirin did not affect resting CBR function. The differences in these findings could be explained by ketorolac and indomethacin blocking TXA 2 and prostaglandin production, whereas low-dose aspirin only inhibits TXA 2 production without affecting PGF 1␣ levels. Also, baroreflex responses to drug infusions and external carotid baroreceptor manipulation may be different when certain products of arachidonic acid breakdown are inhibited. The main finding in this study of augmented CBR-HR sensitivity is in agreement with others in that COX inhibition can alter cardio-vascular control during muscle mechanoreflex and metaboreflex activation in young, healthy humans (8, 25) .
Passive stretch significantly increased HR OP and MAP OP and reset CBR-HR and CBR-MAP function curves to higher HRs and MAPs similarly in all trials. This confirms the ability of this method of muscle mechanoreflex activation to alter cardiovascular control in humans (6 -10, 12, 25) . Passive stretch with and without local metabolite accumulation did not alter G MAX or G OP of CBR-MAP, in agreement with our previous study (10) . In addition, aspirin had no effect on G MAX or G OP of CBR-MAP during stretch with or without metabolite accumulation. This reinforces the concept that muscle mechanoreflex activation can affect CBR-HR sensitivity but not CBR-MAP sensitivity.
It would be of interest to investigate whether aspirin could similarly increase CBR-HR sensitivity during concurrent muscle mechanoreflex and metaboreflex activation in other subject groups, such as older people or patients with cardiovascular disease. A reduction in baroreflex sensitivity is linked to the incidence of sudden cardiac death (37), so if low-dose aspirin were to augment CBR-HR sensitivity during concurrent muscle mechanoreflex and metaboreflex activation in older, healthy people or patients, this could be clinically significant. Many older people and patients take low-dose aspirin daily to reduce the risk of suffering a heart attack or stroke due to its antithrombotic effects (29) . An augmented CBR-HR sensitivity during muscle afferent feedback, i.e., during exercise or physical activity, could be another cardioprotective effect of low-dose aspirin treatment.
We could not provide data that showed TXA 2 and PGF 1␣ levels during stretch with low-dose aspirin and placebo. Using calf stretch and leg ischemia but taking blood samples from the arm meant that blood samples obtained in this way following cuff deflation after stretch would be unlikely to detect any changes in TXA 2 and PGF 1␣ levels. However, baseline TXA 2 levels were significantly reduced with the low-dose aspirin treatment compared with placebo, and baseline PGF 1␣ levels were unaffected.
In conclusion, we have shown that low-dose aspirin augments CBR-HR sensitivity during muscle mechanoreflex and metaboreflex activation in young, healthy humans. This increased sensitivity appears linked to reduced TXA 2 production, Table 6 . Derived variables describing carotid baroreflex control of mean arterial blood pressure during rest and passive stretch with circulatory occlusion (COϩstretch) in the placebo 0%, placebo 70%, aspirin 0% and aspirin 70% trials Fig. 6 . Carotid-vasomotor baroreflex function curves during rest and passive stretch with circulatory occlusion in the placebo 70% and aspirin 70% trials.
which likely plays a role in metabolite sensitization of muscle mechanoreceptors.
